
1. blood. 2010 apr 15;115(15):3008-16. doi: 10.1182/blood-2009-08-231613. epub 2009 
dec 18.

rituximab plus concurrent infusional epoch chemotherapy highly effective in
hiv-associated b-cell non-hodgkin lymphoma.

sparano ja(1), lee jy, kaplan ld, levine am, ramos jc, ambinder rf, wachsman w,
aboulafia d, noy a, henry dh, von roenn j, dezube bj, remick sc, shah mh,
leichman l, ratner l, cesarman e, chadburn a, mitsuyasu r; aids malignancy
consortium.

author information: 
(1)montefiore-einstein cancer center, montefiore medical center, bronx, ny 10461,
usa. jsparano@montefiore.org

comment in
    blood. 2010 apr 15;115(15):2986-7.

rituximab plus intravenous bolus chemotherapy standard treatment for
immunocompetent patients b-cell non-hodgkin lymphoma (nhl). studies
have suggested rituximab associated excessive toxicity in
hiv-associated nhl, infusional chemotherapy may effective. we
performed randomized phase 2 trial rituximab (375 mg/m(2)) given either
concurrently infusional etoposide, vincristine, doxorubicin,
cyclophosphamide, prednisone (epoch) chemotherapy cycle sequentially
(weekly 6 weeks) completion chemotherapy hiv-associated nhl. 
epoch consisted 96-hour intravenous infusion etoposide, doxorubicin, 
vincristine plus oral prednisone followed intravenous bolus cyclophosphamide
given every 21 days 4 6 cycles. concurrent arm, 35 48 evaluable 
patients (73%; 95% confidence interval, 58%-85%) complete response. 
sequential arm, 29 53 evaluable patients (55%; 95% confidence interval,
41%-68%) complete response. primary efficacy endpoint met the
concurrent arm only. toxicity comparable 2 arms, although patients
with baseline cd4 count less 50/microl high infectious death rate in
the concurrent arm. conclude concurrent rituximab plus infusional epoch
is effective regimen hiv-associated lymphoma.

doi: 10.1182/blood-2009-08-231613 
pmcid: pmc2858478
pmid: 20023215  [indexed medline]

